{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:59:48Z","timestamp":1776898788617,"version":"3.51.2"},"reference-count":33,"publisher":"Baskent University","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.6002\/ect.2019.0022","type":"journal-issue","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T07:54:30Z","timestamp":1568706870000},"source":"Crossref","is-referenced-by-count":4,"title":[],"prefix":"10.6002","volume":"22","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","article-title":"Prevention and treatment of postmenopausal osteoporosis","volume":"142","author":"SH","year":"2014","unstructured":"1. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155-170.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"ref1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11255-014-0862-3","article-title":"Osteoporosis after renal transplantation","volume":"47","author":"Dounousi","year":"2015","unstructured":"2. Dounousi E, Leivaditis K, Eleftheriadis T, Liakopoulos V. Osteoporosis after renal transplantation. Int Urol Nephrol. 2015;47(3):503-511.","journal-title":"Int Urol Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Clarke BL, Drake MT. Clinical utility of serum sclerostin measurements. Bonekey Rep. 2013;2:361.","DOI":"10.1038\/bonekey.2013.95"},{"issue":"5","key":"ref3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","unstructured":"4. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537-543.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"ref4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","unstructured":"5. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91-97.","journal-title":"J Med Genet"},{"issue":"2","key":"ref5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11154-015-9311-6","article-title":"Sclerostin and skeletal health","volume":"16","author":"Sharifi","year":"2015","unstructured":"6. Sharifi M, Ereifej L, Lewiecki EM. Sclerostin and skeletal health. Rev Endocr Metab Disord. 2015;16(2):149-156.","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"ref6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","unstructured":"7. Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2014;54(2):168-178.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"ref7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","unstructured":"8. McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33(8):1397-1406.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","unstructured":"9. Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30(2):216-224.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"ref9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000355781","article-title":"Sclerostin blood levels before and after kidney transplantation","volume":"39","author":"Bonani","year":"2014","unstructured":"10. Bonani M, Rodriguez D, Fehr T, et al. Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res. 2014;39(4):230-239.","journal-title":"Kidney Blood Press Res"},{"issue":"10","key":"ref10","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1097\/TP.0000000000001311","article-title":"Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism","volume":"100","author":"Evenepoel","year":"2016","unstructured":"11. Evenepoel P, Claes K, Viaene L, et al. Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism. Transplantation. 2016;100(10):2188-2193.","journal-title":"Transplantation"},{"issue":"7","key":"ref11","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.transproceed.2014.07.024","article-title":"Sclerostin and Dickkopf-1 in post-menopausal renal allograft recipients","volume":"46","author":"Tomei","year":"2014","unstructured":"12. Tomei P, Zaza G, Granata S, et al. Sclerostin and Dickkopf-1 in post-menopausal renal allograft recipients. Transplant Proc. 2014;46(7):2241-2246.","journal-title":"Transplant Proc"},{"key":"ref12","unstructured":"13. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129."},{"key":"ref13","unstructured":"14. The International Society for Densitometry. 2013 ISCD Official Positions - Adult. Middletown, CT: The International Society for Densitometry; 2013. http:\/\/www.iscd.org\/official-positions\/2013-iscd-official-positions-adult\/."},{"key":"ref14","unstructured":"15. Brandenburg VM, Westenfeld R, Ketteler M. The fate of bone after renal transplantation. J Nephrol. 2004;17(2):190-204."},{"issue":"4","key":"ref15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/MNH.0b013e3283546ee0","article-title":"Management of mineral and bone disorder after kidney transplantation","volume":"21","author":"Kalantar-Zadeh","year":"2012","unstructured":"16. Kalantar-Zadeh K, Molnar MZ, Kovesdy CP, Mucsi I, Bunnapradist S. Management of mineral and bone disorder after kidney transplantation. Curr Opin Nephrol Hypertens. 2012;21(4):389-403.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"ref16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"Modder","year":"2011","unstructured":"17. Modder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26(2):373-379.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"ref17","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1002\/jbmr.1718","article-title":"High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study","volume":"27","author":"Ardawi","year":"2012","unstructured":"18. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res. 2012;27(12):2592-2602.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"ref18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00198-012-1978-x","article-title":"Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study","volume":"24","author":"Garnero","year":"2013","unstructured":"19. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013;24(2):489-494.","journal-title":"Osteoporos Int"},{"issue":"1","key":"ref19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1210\/jc.2011-2152","article-title":"Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults","volume":"97","author":"Amrein","year":"2012","unstructured":"20. Amrein K, Amrein S, Drexler C, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012;97(1):148-154.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"ref20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1530\/EJE-12-1074","article-title":"Serum sclerostin levels in men with idiopathic osteoporosis","volume":"168","author":"Lapauw","year":"2013","unstructured":"21. Lapauw B, Vandewalle S, Taes Y, et al. Serum sclerostin levels in men with idiopathic osteoporosis. Eur J Endocrinol. 2013;168(4):615-620.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"ref21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00223-016-0160-4","article-title":"Decreased plasma levels of sclerostin but not Dickkopf-1 are associated with an increased prevalence of osteoporotic fracture and lower bone mineral density in postmenopausal Korean women","volume":"99","author":"Lim","year":"2016","unstructured":"22. Lim Y, Kim CH, Lee SY, et al. Decreased plasma levels of sclerostin but not Dickkopf-1 are associated with an increased prevalence of osteoporotic fracture and lower bone mineral density in postmenopausal Korean women. Calcif Tissue Int. 2016;99(4):350-359.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"ref22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00198-010-1525-6","article-title":"Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide","volume":"23","author":"Polyzos","year":"2012","unstructured":"23. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int. 2012;23(3):1171-1176.","journal-title":"Osteoporos Int"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41100-016-0024-4","article-title":"Role of sclerostin in the pathogenesis of chronic kidney disease-mineral bone disorder","volume":"2","author":"Asamiya","year":"2016","unstructured":"24. Asamiya Y, Tsuchiya K, Nitta K. Role of sclerostin in the pathogenesis of chronic kidney disease-mineral bone disorder. Renal Replacement Therapy. 2016;2:8.","journal-title":"Renal Replacement Therapy"},{"issue":"2","key":"ref24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","unstructured":"25. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37(2):148-158.","journal-title":"Bone"},{"issue":"4","key":"ref25","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1210\/jc.2009-2283","article-title":"Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women","volume":"95","author":"Mirza","year":"2010","unstructured":"26. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95(4):1991-1997.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"ref26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10735-007-9096-3","article-title":"Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone","volume":"38","author":"Silvestrini","year":"2007","unstructured":"27. Silvestrini G, Ballanti P, Leopizzi M, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol. 2007;38(4):261-269.","journal-title":"J Mol Histol"},{"issue":"12","key":"ref27","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1002\/jbmr.479","article-title":"Determinants of serum sclerostin in healthy pre- and postmenopausal women","volume":"26","author":"Ardawi","year":"2011","unstructured":"28. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011;26(12):2812-2822.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"ref28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2215\/CJN.07670712","article-title":"The relation between renal function and serum sclerostin in adult patients with CKD","volume":"8","author":"Pelletier","year":"2013","unstructured":"29. Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):819-823.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"ref29","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1210\/jc.2014-2372","article-title":"Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients","volume":"99","author":"Ishimura","year":"2014","unstructured":"30. Ishimura E, Okuno S, Ichii M, et al. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab. 2014;99(11):4315-4320.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Kidney Disease: Improving Global Outcomes CKDMBDUWG. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59.","DOI":"10.1016\/j.kisu.2017.04.001"},{"issue":"6","key":"ref31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/MED.0000000000000196","article-title":"Bone disease in post-transplant patients","volume":"22","author":"Jeon","year":"2015","unstructured":"32. Jeon HJ, Kim H, Yang J. Bone disease in post-transplant patients. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):452-458.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"ref32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0272-6386(04)00955-2","article-title":"Histologic evolution of bone disease 6 months after successful kidney transplantation","volume":"44","author":"Cruz","year":"2004","unstructured":"33. Cruz EA, Lugon JR, Jorgetti V, Draibe SA, Carvalho AB. Histologic evolution of bone disease 6 months after successful kidney transplantation. Am J Kidney Dis. 2004;44(4):747-756.","journal-title":"Am J Kidney Dis"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T09:05:51Z","timestamp":1724403951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2024\/22\/7\/0\/514\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2019.0022","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}